Published overnight - couple of solid quotes in there :)
https://www.imperial.ac.uk/be-inspired/magazine/issue-52/a-working-life/
For anyone familiar with the report as presented at the ATS, you can see they way they've toplined the information to make it sharp and punchy.
As very quickly pointed out by others, nothing new here but we knew that already.
Market opens tomorrow in US, RM presso on wed. Keep it coming pls SNG.
I expect TW and the Synairgen team at University of Southampton don't work for free, nor their facilities. I would be very interested to know what (if any) impact this trial will have on the companies revenue/funding.
Thanks for posting Fruitsnveg. Thought it deserved its own thread
https://www.isrctn.com/ISRCTN49183956
"When is the study starting and how long is it expected to run for?
November 2021 to June 2024
Where is the study run from?
Southampton General Hospital (UK)
Who is funding the study?
1. Janssen Pharmaceuticals (USA)
2. AstraZeneca (UK)
Who is the main contact?
UNIVERSAL Study Team
UNIVERSAL@soton.ac.uk"
darkbrandonmeme.jpg
https://www.reuters.com/world/biden-request-117-bln-ukraine-aid-224-bln-covid-relief-2022-09-02/
Nice little write up on the early days of synairgen and the discovery and innovation the company has accomplished over the last 20 years.
https://issuu.com/university_of_southampton/docs/reaction_magazine_summer_2022/s/16390083
"Following her PhD, she worked with Professor Donna Davies and Professor Sir Stephen Holgate, initially looking at these growth factors and signalling pathways in the repair of asthmatic airways in responses to different environmental insults.
Her research involved taking cells from airways and growing these at an air-liquid interface. “I was able to grow miniature models of the airways to replicate the lung lining – layers of cells with specialised mucus producing cells, and cells with beating cilia which help clear mucus and irritants from the airways,” she said. ‘’My work using these models and biopsies compared healthy and diseased airways’ responses to external insults and looked at factors involved in the underlying disease changes observed in the airways.”
Cheers Fruits. It is certainly shaping up that way.
Noted this one has the same title as PMs planned presentation at the world anti viral Congress in Nov and not "Sprinter P3 etc" as TW is presenting at the ERS on Monday
https://www.terrapinn.com/conference/world-antiviral-congress/speaker-phillip-MONK.stm
https://www.intertek.com/pharmaceutical/events/inhaled-nasal-biologics-dna-forum/
Title: Inhaled IFN-ß (SNG001) for the treatment of COVID-19 and other severe viral lung infections
Phillip Monk, Chief Scientific Officer, Synairgen Research Ltd
Not sure if it was discussed earlier but todays linkedin post from the company confirms TW is presenting sprinter results at the ERS
https://www.linkedin.com/company/synairgen-research-ltd/
There's the whole covid black fungus thing as well.
https://www.bbc.com/news/world-asia-india-57027829
Very much thinking out loud here but sprinter of course ran in India and I believe upwards of 90 patients were randomised - could there be a signal re black fungus?
They should try putting in directly in to the lungs.
[28,29], this pathway could represent a mechanism, how fungal priming of IFN-I responses builds antiviral countermeasures. Given the potential of commensal Candida species to induce IFN-I responses [8,10,20], it may be worth investigating, whether their colonization shape smucosal antiviral immunity.5. Is IFN-I immunotherapy an option?Immunotherapy is an increasingly recognized essential strategy to improve the outcome of fungal infections. These therapies either can augment a compromised immune system or sup-press detrimental inflammatory responses. Thus, this is particularly attractive for infections inimmuno compromised patients or infections associated with immunopathology.The capacity of IFN-I to improve several aspects of antifungal host defense warrants their exploration as candidates for immunotherapy of mucosal fungal infections.Particularly, treatment of VVC is complex due to the interplay between fungal pathogenic-ity and immunopathology underlying its pathogenesis. While immunotherapy for VVC hasnot yet been broadly explored, IFNawas successful in increasing resistance to VVC in a rat model [22]. Besides, IFN-I treatment can have diverse beneficial effects during VVC by increasing epithelial resistance to infection [20,22] and inhibiting detrimental inflammatory responses [20]. This evidence suggesting a protective role of IFN-I at mucosal barriers supports that specifically mucosal, rather than systemic, disease may benefit from such therapy. Con-cerning aspergillosis, chronic granulomatous disease (CGD) patients are another group that potentially could ultimately benefit from IFN-I immunotherapy, as IFN-I-inducing poly I:Ctreatment in mice neutrophil-dependent improved outcome of aspergillosis [30]. Further-more, exogenous IFN-I administration rescued inadequate antifungal responses in dectin-1-/-mice [16]. IFN-I signaling is well documented for its role in maintaining intestinal barrier homeostasis. Therefore, it is tempting to speculate that IFN-I immunotherapy may be a valu-able approach to reduce C.albicans translocation through improving epithelial barrier func-tion. It is, however, difficult to estimate how such an immunotherapy affects immunocompromised patients. Yet in the context of inflammatory bowel diseases (IBDs),IFN-I are discussed as an immunomodulatory treatment strategy. Given the evidence for a key role of C.albicans pathogenicity mechanisms in IBD [31], IFN-I therapy may both modulate inflammatory responses and increase epithelial resistance to fungal pathogenicity. IFN-I medi-ate cross-talk between epithelial cells and the immune system during commensalism and infection, potentially making them an attractive therapeutic target for fungal infections in the gut, lung, and vaginal mucosa.
Wow what a s**tshow.
Hell of a lot of effort on a bank holiday Monday to make sure no one actually discusses RMs presentation at this conference.
I assume what we are trying to avoid is that the most likely explanation for the title TBC - RMs presentation is under embargo due to containing commercially sensitive info.
Thank you for sharing that paper Tommy - the conclusion is pretty strong
"Another important implication of our study is the potentially expanded utility of using exogenous administration of type I and III interferons as immunotherapies to combat fungal infections. In our previous work, we showed that combination treatment with type I (IFN-a2) and type III (IFN-?3) IFNs was able to enhance the function of neutrophils in monocytopenic mice (Espinosa et al., 2017). In the current study, we found that administration of the same combination of IFNs to dectin-1-/- mice helped improve neutrophil function and overall control of fungal infection in the lung. Ongoing efforts in our lab are focused in testing the potential benefit of combination IFN therapies in diverse mouse models of susceptibility to IA. Recombinant type I IFNs, including pegylated IFN-a2, are FDA-approved therapeutics in current use against a variety of conditions including various malignancies and viral infections. Formulations of pegylated-IFN-? are currently in phase 2 trials and have shown good promise for patient tolerability of side effects and efficacy against hepatitis B infection (Phillips et al., 2017). Therefore, future studies from our lab and others could provide critical proof-of-principle data to support future clinical trials to test the potential use of combination treatments with type I and III IFNs in the improvement of immune function and antifungal defense in susceptible patients."
Ghia
"In-house resource has both pro’s and cons it certainly suggests they have a long term need but doesn’t suggest short term urgency."
Generally agree w this which I think is why it's so intriguing!
Unless like some job adverts what's on the tin isn't always exactly inside - it's not an industry to eff around w potential employees.
It's another breadcrumb tho and certainly a positive that the company has something to say.